Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Gallbladder and bile duct cancers are rare but aggressive malignancies.
• Early-stage diagnosis allows for surgical resection, but adjuvant therapy is often considered to improve outcomes.
• The role of adjuvant chemotherapy and radiotherapy in these early stages remains debated.

Purpose of the Study:

• To evaluate the efficacy of adjuvant therapy, including chemotherapy and radiotherapy, in patients with early-stage (I-III) gallbladder and bile duct cancers.
• To analyze the impact of adjuvant treatment on disease-free survival (DFS) and overall survival.

Main Methods:

• Retrospective analysis of 52 patients with resected early-stage gallbladder (n=36) and bile duct (n=16) cancers.
• Evaluation of clinical, pathological, treatment, and survival data from August 2002 to November 2009.
• Comparison of outcomes between patients who received adjuvant therapy (chemotherapy and/or radiotherapy) and those who did not.

Main Results:

• Approximately half of the patients (48.1%) received adjuvant therapy, most commonly a 5-fluorouracil (5-FU)-based regimen.
• Patients receiving adjuvant therapy were younger and had more frequent poor prognostic factors (high tumor grade, vascular invasion).
• No significant difference in median DFS (11.4 vs. 8.2 months) or overall survival was observed between the adjuvant therapy and no-adjuvant therapy groups (p=0.67 and p=0.97, respectively).

Conclusions:

• This study did not confirm a survival advantage for adjuvant chemotherapy and/or radiotherapy in early-stage gallbladder and bile duct cancers.
• Previous findings suggesting a benefit from 5-FU-based chemotherapy were not replicated.
• Prospective clinical trials with standardized regimens and larger patient cohorts are necessary to definitively establish the role of adjuvant therapy in these cancers.